Cargando…

Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma

PURPOSE: The tumor suppressor candidate 3 (TUSC3) has been considered to be closely associated with the occurrence, development and invasion of various malignant tumors. However, the expression of TUSC3 in hepatocellular carcinoma (HCC) tissues remains ambiguous. The purpose of this research was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheng, Xu-Ren, Xing, Song-Ge, Wang, Run-Dong, Chen, Kang, Jia, Wei-Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825997/
https://www.ncbi.nlm.nih.gov/pubmed/29503566
http://dx.doi.org/10.2147/OTT.S153381
_version_ 1783302272444268544
author Sheng, Xu-Ren
Xing, Song-Ge
Wang, Run-Dong
Chen, Kang
Jia, Wei-Dong
author_facet Sheng, Xu-Ren
Xing, Song-Ge
Wang, Run-Dong
Chen, Kang
Jia, Wei-Dong
author_sort Sheng, Xu-Ren
collection PubMed
description PURPOSE: The tumor suppressor candidate 3 (TUSC3) has been considered to be closely associated with the occurrence, development and invasion of various malignant tumors. However, the expression of TUSC3 in hepatocellular carcinoma (HCC) tissues remains ambiguous. The purpose of this research was to investigate the expression of TUSC3 in HCC tissues and analyze the relationship between TUSC3 levels and clinicopathological characteristics and prognosis of HCC patients. MATERIALS AND METHODS: Immunohistochemistry was used to detect the expression of TUSC3 in HCC and the corresponding para-cancerous tissues from 92 samples of HCC patients. mRNA and protein expression levels of TUSC3 were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot assays in 25 paired HCC and corresponding adjacent nontumor tissues. Furthermore, statistical analysis was applied to evaluate the correlation between TUSC3 level and the clinicopathological features and prognosis of HCC patients. RESULTS: Immunohistochemical assay indicated that the expression of TUSC3 was significantly lower in HCC tissues when compared with the corresponding para-cancerous tissues (χ(2)=11.512, P=0.001). The analysis of clinicopathological characteristics showed that low expression of TUSC3 in HCC tissues was significantly associated with Edmondson grade, Barcelona Clinic Liver Cancer stage and tumor size (P=0.008, 0.009 and 0.020, respectively). Univariate analysis showed that the expression of TUSC3 was strongly correlated with overall survival (OS) and disease-free survival (DFS) after radical surgery in HCC patients (P<0.001, P<0.001, respectively). Multivariate analysis revealed that the TUSC3 level was an independent risk factor for OS and DFS in HCC patients (P=0.001, P<0.001, respectively). Results of qRT-PCR and Western blot assays indicated that the level of TUSC3 in HCC tissues was significantly lower than that in the corresponding adjacent noncancerous tissues (P<0.01, P<0.001). CONCLUSION: The expression of TUSC3 in HCC was significantly downregulated and was correlated with tumor progression and prognosis, which could be used as an independent predictor of prognosis in HCC patients.
format Online
Article
Text
id pubmed-5825997
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-58259972018-03-02 Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma Sheng, Xu-Ren Xing, Song-Ge Wang, Run-Dong Chen, Kang Jia, Wei-Dong Onco Targets Ther Original Research PURPOSE: The tumor suppressor candidate 3 (TUSC3) has been considered to be closely associated with the occurrence, development and invasion of various malignant tumors. However, the expression of TUSC3 in hepatocellular carcinoma (HCC) tissues remains ambiguous. The purpose of this research was to investigate the expression of TUSC3 in HCC tissues and analyze the relationship between TUSC3 levels and clinicopathological characteristics and prognosis of HCC patients. MATERIALS AND METHODS: Immunohistochemistry was used to detect the expression of TUSC3 in HCC and the corresponding para-cancerous tissues from 92 samples of HCC patients. mRNA and protein expression levels of TUSC3 were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot assays in 25 paired HCC and corresponding adjacent nontumor tissues. Furthermore, statistical analysis was applied to evaluate the correlation between TUSC3 level and the clinicopathological features and prognosis of HCC patients. RESULTS: Immunohistochemical assay indicated that the expression of TUSC3 was significantly lower in HCC tissues when compared with the corresponding para-cancerous tissues (χ(2)=11.512, P=0.001). The analysis of clinicopathological characteristics showed that low expression of TUSC3 in HCC tissues was significantly associated with Edmondson grade, Barcelona Clinic Liver Cancer stage and tumor size (P=0.008, 0.009 and 0.020, respectively). Univariate analysis showed that the expression of TUSC3 was strongly correlated with overall survival (OS) and disease-free survival (DFS) after radical surgery in HCC patients (P<0.001, P<0.001, respectively). Multivariate analysis revealed that the TUSC3 level was an independent risk factor for OS and DFS in HCC patients (P=0.001, P<0.001, respectively). Results of qRT-PCR and Western blot assays indicated that the level of TUSC3 in HCC tissues was significantly lower than that in the corresponding adjacent noncancerous tissues (P<0.01, P<0.001). CONCLUSION: The expression of TUSC3 in HCC was significantly downregulated and was correlated with tumor progression and prognosis, which could be used as an independent predictor of prognosis in HCC patients. Dove Medical Press 2018-02-21 /pmc/articles/PMC5825997/ /pubmed/29503566 http://dx.doi.org/10.2147/OTT.S153381 Text en © 2018 Sheng et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Sheng, Xu-Ren
Xing, Song-Ge
Wang, Run-Dong
Chen, Kang
Jia, Wei-Dong
Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma
title Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma
title_full Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma
title_fullStr Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma
title_full_unstemmed Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma
title_short Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma
title_sort low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825997/
https://www.ncbi.nlm.nih.gov/pubmed/29503566
http://dx.doi.org/10.2147/OTT.S153381
work_keys_str_mv AT shengxuren lowlevelsoftumorsuppressorcandidate3predictpoorprognosisofpatientswithhepatocellularcarcinoma
AT xingsongge lowlevelsoftumorsuppressorcandidate3predictpoorprognosisofpatientswithhepatocellularcarcinoma
AT wangrundong lowlevelsoftumorsuppressorcandidate3predictpoorprognosisofpatientswithhepatocellularcarcinoma
AT chenkang lowlevelsoftumorsuppressorcandidate3predictpoorprognosisofpatientswithhepatocellularcarcinoma
AT jiaweidong lowlevelsoftumorsuppressorcandidate3predictpoorprognosisofpatientswithhepatocellularcarcinoma